BMY Stock UPDATES Bristol-Myers Squibb Company (BMY) 51.51 09/21/2014
Post# of 273318
Posted On: 09/21/2014 11:23:38 PM
Bristol-Myers Squibb Company (BMY) 51.51 $BMY
Final Glance: Pharmaceuticals companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:40PM CDT
Bristol-Myers' (BMY) Yervoy gained Canadian approval for treating adults newly diagnosed with advanced melanoma.
Midday Glance: Pharmaceuticals companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb (BMY) Approaches New Upside Target of $51.67
Comtex SmarTrend(R) - Fri Sep 19, 11:42AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $51.16 today and has reached the first level of resistance at $51.39. Analysts will be watching for a cross of the next upside pivot targets of $51.67 and $52.18.
Early Glance: Pharmaceuticals companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 18, 9:57AM CDT
Big Pharma's battle with the patent cliff has led to drastic changes across the healthcare sector. Companies have slashed workforces, changed the focus of their product and clinical portfolios, and even moved abroad to lower their effective tax...
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
Frances K. Heller Rejoins Zafgen Board of Directors
GlobeNewswire - Thu Sep 18, 6:06AM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Frances K. Heller will rejoin Zafgen's Board of Directors and will also be a member of the Audit Committee. Ms. Heller previously served as a Zafgen director from October 2011 to December 2013, and left the Board as she joined Bristol-Myers Squibb to lead its business development group. Zafgen's Board currently includes eight directors, seven of whom are independent.
Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:00PM CDT
Five Prime Therapeutics, Inc. (FPRX) will get $1.5 million with Glaxo exercising its option under their 2010 agreement.
Bristol-Myers Squibb Company 's board to pay dividends
M2 - Wed Sep 17, 6:36AM CDT
The board of directors of biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday declared a quarterly dividend of USD0.36 per share on the USD0.10 par value common stock.
Bristol-Myers Squibb Announces Dividend
Business Wire - Tue Sep 16, 3:30PM CDT
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 3, 2014, to stockholders of record at the close of business on October 3, 2014.
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's "Storm The Castle" Stock
at The Street - Tue Sep 16, 12:48PM CDT
Trade-Ideas LLC identified Bristol-Myers Squibb Company (BMY) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
While the Overall Use of Rheumatoid Arthritis Biologics Remains Stable in the Major European Markets, Newer Agents are Gaining Momentum over More Mature Products
PR Newswire - Tue Sep 16, 10:00AM CDT
Decision Resources Group finds that the percentage of rheumatoid arthritis (RA) patients treated with a biologic agent by rheumatologists has remained relatively constant since 2012 in the major European markets (France, Germany, Italy, Spain and the United Kingdom). Within all levels of disease severity, there appears to be fairly limited opportunity overall for increased use of biologics based on the gap between the percentage of patients that are treated and the percentage of patients considered appropriate for treatment. However, several relatively newer agents (UCB's Cimzia, Roche's RoActemra and Janssen's Simponi) and an agent with a new subcutaneous formulation (Bristol-Myers Squibb's Orencia) have experienced an increase in their reported patient share at the expense of the more established TNF-alpha inhibitors (Pfizer's Enbrel, AbbVie's Humira, Janssen's Remicade).
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Final Glance: Pharmaceuticals companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:40PM CDT
Bristol-Myers' (BMY) Yervoy gained Canadian approval for treating adults newly diagnosed with advanced melanoma.
Midday Glance: Pharmaceuticals companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb (BMY) Approaches New Upside Target of $51.67
Comtex SmarTrend(R) - Fri Sep 19, 11:42AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $51.16 today and has reached the first level of resistance at $51.39. Analysts will be watching for a cross of the next upside pivot targets of $51.67 and $52.18.
Early Glance: Pharmaceuticals companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 18, 9:57AM CDT
Big Pharma's battle with the patent cliff has led to drastic changes across the healthcare sector. Companies have slashed workforces, changed the focus of their product and clinical portfolios, and even moved abroad to lower their effective tax...
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
Frances K. Heller Rejoins Zafgen Board of Directors
GlobeNewswire - Thu Sep 18, 6:06AM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Frances K. Heller will rejoin Zafgen's Board of Directors and will also be a member of the Audit Committee. Ms. Heller previously served as a Zafgen director from October 2011 to December 2013, and left the Board as she joined Bristol-Myers Squibb to lead its business development group. Zafgen's Board currently includes eight directors, seven of whom are independent.
Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:00PM CDT
Five Prime Therapeutics, Inc. (FPRX) will get $1.5 million with Glaxo exercising its option under their 2010 agreement.
Bristol-Myers Squibb Company 's board to pay dividends
M2 - Wed Sep 17, 6:36AM CDT
The board of directors of biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday declared a quarterly dividend of USD0.36 per share on the USD0.10 par value common stock.
Bristol-Myers Squibb Announces Dividend
Business Wire - Tue Sep 16, 3:30PM CDT
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 3, 2014, to stockholders of record at the close of business on October 3, 2014.
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's "Storm The Castle" Stock
at The Street - Tue Sep 16, 12:48PM CDT
Trade-Ideas LLC identified Bristol-Myers Squibb Company (BMY) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
While the Overall Use of Rheumatoid Arthritis Biologics Remains Stable in the Major European Markets, Newer Agents are Gaining Momentum over More Mature Products
PR Newswire - Tue Sep 16, 10:00AM CDT
Decision Resources Group finds that the percentage of rheumatoid arthritis (RA) patients treated with a biologic agent by rheumatologists has remained relatively constant since 2012 in the major European markets (France, Germany, Italy, Spain and the United Kingdom). Within all levels of disease severity, there appears to be fairly limited opportunity overall for increased use of biologics based on the gap between the percentage of patients that are treated and the percentage of patients considered appropriate for treatment. However, several relatively newer agents (UCB's Cimzia, Roche's RoActemra and Janssen's Simponi) and an agent with a new subcutaneous formulation (Bristol-Myers Squibb's Orencia) have experienced an increase in their reported patient share at the expense of the more established TNF-alpha inhibitors (Pfizer's Enbrel, AbbVie's Humira, Janssen's Remicade).
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
(0)
(0)